GW&K Investment Management LLC trimmed its position in Cambrex Co. (NYSE:CBM) by 2.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 425,859 shares of the biotechnology company’s stock after selling 9,168 shares during the period. GW&K Investment Management LLC owned about 1.27% of Cambrex worth $19,934,000 as of its most recent SEC filing.
Other large investors have also recently made changes to their positions in the company. Baldwin Investment Management LLC boosted its holdings in Cambrex by 7.3% during the 2nd quarter. Baldwin Investment Management LLC now owns 5,900 shares of the biotechnology company’s stock valued at $276,000 after acquiring an additional 400 shares during the period. Magnus Financial Group LLC bought a new stake in Cambrex during the 2nd quarter valued at $215,000. Chicago Equity Partners LLC bought a new stake in Cambrex during the 2nd quarter valued at $585,000. Everence Capital Management Inc. bought a new stake in Cambrex during the 2nd quarter valued at $239,000. Finally, Swiss National Bank raised its position in Cambrex by 2.1% during the 2nd quarter. Swiss National Bank now owns 62,500 shares of the biotechnology company’s stock valued at $2,926,000 after purchasing an additional 1,300 shares in the last quarter.
Several research firms have recently commented on CBM. Craig Hallum lowered Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price target for the company. in a research report on Monday, August 12th. Zacks Investment Research lowered Cambrex from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. Robert W. Baird lowered Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 price target for the company. in a research report on Friday, May 3rd. They noted that the move was a valuation call. William Blair lowered Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price on the stock. in a research report on Wednesday, August 7th. Finally, First Analysis lowered Cambrex from a “strong-buy” rating to an “outperform” rating and upped their target price for the company from $45.00 to $55.00 in a research report on Tuesday, May 7th. Five equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and an average price target of $52.00.
Shares of CBM traded down $0.01 during mid-day trading on Friday, reaching $59.26. The company had a trading volume of 673,890 shares, compared to its average volume of 1,356,664. The stock has a market capitalization of $2.00 billion, a P/E ratio of 21.39, a PEG ratio of 4.63 and a beta of 2.36. Cambrex Co. has a 52-week low of $33.80 and a 52-week high of $69.43. The company has a quick ratio of 1.77, a current ratio of 2.44 and a debt-to-equity ratio of 0.78. The stock has a 50 day moving average of $49.65 and a two-hundred day moving average of $43.28.
Cambrex Company Profile
Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.
Recommended Story: What are the risks of holding treasury bonds?
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.